P Sinnaeve
Overview
Explore the profile of P Sinnaeve including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
109
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bennett J, Adriaenssens T, McCutcheon K, Dens J, Desmet W, Sinnaeve P, et al.
Catheter Cardiovasc Interv
. 2018 Mar;
92(6):E375-E380.
PMID: 29536609
Objectives: We evaluated healing responses with optical coherence tomography, and long-term clinical outcomes after treatment with a dedicated stent versus a conventional culotte technique. Background: Dedicated bifurcation stents have been...
2.
Argacha J, Collart P, Wauters A, Kayaert P, Lochy S, Schoors D, et al.
Int J Cardiol
. 2016 Aug;
223:300-305.
PMID: 27541680
Background: Previous studies have shown that air pollution particulate matter (PM) is associated with an increased risk for myocardial infarction. The effects of air pollution on the risk of ST-elevation...
3.
Douxfils J, Michel S, Beauloye C, Goethals M, Hainaut P, Heidbuchel H, et al.
J Pharm Belg
. 2013 May;
(1):28-36.
PMID: 23638610
Rivaroxaban is one of the new oral anticoagulants (NOACs). It has many potential advantages in comparison with Vitamin K Antagonists (VKA). It has a predictable anticoagulant effect and does not...
4.
5.
Ughi G, Adriaenssens T, Onsea K, Kayaert P, Dubois C, Sinnaeve P, et al.
Int J Cardiovasc Imaging
. 2011 Feb;
28(2):229-41.
PMID: 21347593
The implantation of intracoronary stents is currently the standard approach for the treatment of coronary atherosclerotic disease. The widespread adoption of this technology has boosted an intensive research activity in...
6.
Engelen S, Sinnaeve P, Damme H, Verhamme P
Acta Anaesthesiol Belg
. 2011 Jan;
61(3):139-43.
PMID: 21268568
Antiplatelet drugs are the cornerstone treatment in the secondary prevention of arterial thrombosis. Until recently, their intake was interrupted in the perioperative period because of fear for bleeding, but new...
7.
Sinnaeve P, Van de Werf F
Thromb Res
. 2001 Sep;
103 Suppl 1:S71-9.
PMID: 11567672
Thrombolytic agents have become the corner stone in the treatment of acute myocardial infarction. However, the current agents are far from perfect. New thrombolytic drugs have been designed to overcome...
8.
Sinnaeve P, Chiche J, Nong Z, Varenne O, van Pelt N, Gillijns H, et al.
Circ Res
. 2001 Jan;
88(1):103-9.
PMID: 11139481
In vascular smooth muscle cells, NO stimulates the synthesis of cGMP by soluble guanylate cyclase (sGC), a heterodimer composed of alpha(1) and beta(1) subunits. NO/cGMP signal transduction affects multiple cell...
9.
Collen D, Sinnaeve P, Demarsin E, Moreau H, De Maeyer M, Jespers L, et al.
Circulation
. 2000 Oct;
102(15):1766-72.
PMID: 11023930
Background: Thrombolytic therapy of acute myocardial infarction (AMI) is evolving toward bolus administration. Derivatization of proteins with polyethylene glycol (PEG) may reduce their clearance. Methods And Results: A staphylokinase (SakSTAR)...
10.
Varenne O, Sinnaeve P, Gillijns H, Iung B, Laurysens V, Meurrens K, et al.
Hum Gene Ther
. 2000 Jul;
11(9):1329-39.
PMID: 10890742
Local intracoronary delivery of recombinant adenoviruses expressing anti-migratory or anti-proliferative proteins including human constitutive endothelial nitric oxide synthase (NOS3), plasminogen activator inhibitor 1 (PAI-1), or herpesvirus thymidine kinase (TK) (combined...